Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








TB-Related Articles							Updated February 3, 2023
																	Related Pages
										Return to Main Menu**2022 DTBE Publications**
Althomsons SP, Winglee K, Heilig CM, Talarico S, Silk B, Wortham J, Hill AN, Navin TR. Using Machine Learning Techniques and National Tuberculosis Surveillance Data to Predict Excess Growth in Genotyped Tuberculosis Clusters. Am J Epidemiol. 2022 Jul 2:kwac117. doi: 10.1093/aje/kwac117. Epub ahead of print. PMID: 35780450.
Burzynski J, Mangan JM, Lam CK, Macaraig M, Salerno MM, deCastro BR, Goswami ND, Lin CY, Schluger NW, Vernon A; eDOT Study Team. In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial. JAMA Netw Open. 2022 Jan 4;5(1):e2144210. doi: 10.1001/jamanetworkopen.2021.44210. PMID: 35050357; PMCID: PMC8777548.Year20232022202120202019201820172016201520142013Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 25;71(8):285-289. doi: 10.15585/mmwr.mm7108a1. PMID: 35202353.
Deutsch-Feldman M, Springer YP, Felix D, Tsang CA, Brostrom R, Haddad M. Tuberculosis Among Native Hawaiian and Other Pacific Islander Persons: United States and U.S.-Affiliated Pacific Islands, 2010-2019. Health Equity. 2022 Jun 27;6(1):476-484. doi: 10.1089/heq.2022.0065. PMID: 35801148; PMCID: PMC9257550.
Filardo TD, Feng PJ, Pratt RH, Price SF, Self JL. Tuberculosis – United States, 2021. MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):441-446. doi: 10.15585/mmwr.mm7112a1. PMID: 35324877; PMCID: PMC8956339.
Goswami ND, Ashkin D, Haley CA; BAM Project Team. Pretomanid in the Treatment of Patients with Tuberculosis in the United States. N Engl J Med. 2022 Sep 1;387(9):850-852. doi: 10.1056/NEJMc2119461. PMID: 36053513.
Ho CS, Feng PJ, Narita M, Stout JE, Chen M, Pascopella L, Garfein R, Reves R, Katz DJ; Tuberculosis Epidemiologic Studies Consortium. Discordant results of tests for tuberculosis reconsidered – Authors’ reply. Lancet Infect Dis. 2022 Feb;22(2):164-165. doi: 10.1016/S1473-3099(21)00805-7. PMID: 35092787.
Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed A, Miller TL, Pettit AC, Khurana R, Whipple M, Katz D, Largen A, Krueger A, Shah M. Evaluation of the latent tuberculosis care cascade among public health clinics in the United States. Clin Infect Dis. 2022 Apr 1:ciac248. doi: 10.1093/cid/ciac248. Epub ahead of print. PMID: 35363249.
Holzman SB, Perry A, Keh C, Salcedo K, Narita M, Ahmed A, Katz D, Krueger A, Shah M. Reply to Gaskell, et al. Clin Infect Dis. 2022 Jul 23:ciac583. doi: 10.1093/cid/ciac583. Epub ahead of print. PMID: 35869850.
Kim S, Cohen T, Horsburgh CR, Miller JW, Hill AN, Marks SM, Li R, Kammerer JS, Salomon JA, Menzies NA. Trends, Mechanisms, and Racial/Ethnic Differences of Tuberculosis Incidence in the US-Born Population Aged 50 Years or Older in the United States. Clin Infect Dis. 2022 May 3;74(9):1594-1603. doi: 10.1093/cid/ciab668. PMID: 34323959; PMCID: PMC8799750.
Krugman J, Chorba T. When a Touch of Gold Was Used to Heal the King’s Evil. Emerg Infect Dis. 2022 Mar;28(3):765–7. doi: 10.3201/eid2803.AC2803. PMCID: PMC8888212.
Liu Y, Posey DL, Yang Q, Weinberg MS, Maloney SA, Lambert LA, Ortega LS, Marano N, Cetron MS, Phares CR. Multidrug-Resistant Tuberculosis in U.S.-Bound Immigrants and Refugees. Ann Am Thorac Soc. 2022 Jun;19(6):943-951. doi: 10.1513/AnnalsATS.202105-580OC. PMID: 34941475; PMCID: PMC9169124.
Pang AH, Green KD, Chandrika NT, Garzan A, Punetha A, Holbrook SYL, Willby MJ, Posey JE, Tsodikov OV, Garneau-Tsodikova S. Discovery of substituted benzyloxy-benzylamine inhibitors of acetyltransferase Eis and their anti-mycobacterial activity. Eur J Med Chem. 2022 Aug 18;242:114698. doi: 10.1016/j.ejmech.2022.114698. Epub ahead of print. PMID: 36037791.
Parmer J, Macario E, Tatum K, Brackett A, Allen L, Picard R, DeLuca N, Dowling M. Latent tuberculosis infection: Misperceptions among non-U.S.-born-populations from countries where tuberculosis is common. Glob Public Health. 2022 Aug;17(8):1728-1742. doi: 10.1080/17441692.2021.1947342. Epub 2021 Jul 6. PMID: 34228584; PMCID: PMC8733044.
Pettit AC, Phillips PP, Kurbatova E, Vernon A, Nahid P, Dawson R, Dooley KE, Sanne I, Waja Z, Mohapi L, Podany AT, Samaneka W, Savic RM, Johnson JL, Muzanyi G, Lalloo UG, Bryant K, Sizemore E, Scott N, Dorman SE, Chaisson RE, Swindells S; Tuberculosis Trials Consortium (TBTC) Study 31/AIDS Clinical Trials Group (ACTG) A5349 study team. Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV (S31/A5349). Clin Infect Dis. 2022 Aug 30:ciac707. doi: 10.1093/cid/ciac707. Epub ahead of print. PMID: 36041016.
Phares CR, Liu Y, Wang Z, Posey DL, Lee D, Jentes ES, Weinberg M, Mitchell T, Stauffer W, Self JL, Marano N. Disease Surveillance Among U.S.-Bound Immigrants and Refugees – Electronic Disease Notification System, United States, 2014-2019. MMWR Surveill Summ. 2022 Jan 21;71(2):1-21. doi: 10.15585/mmwr.ss7102a1. PMID: 35051136; PMCID: PMC8791661.
Phillips PPJ, Kurbatova EV, Dorman SE. Four-Month Rifapentine Regimens for Tuberculosis. Reply. N Engl J Med. 2022 Mar 17;386(11):1095-1096. doi: 10.1056/NEJMc2114483. PMID: 35294823.
Raz KM, Talarico S, Althomsons SP, Kammerer JS, Cowan LS, Haddad MB, McDaniel CJ, Wortham JM, France AM, Powell KM, Posey JE, Silk BJ. Molecular surveillance for large outbreaks of tuberculosis in the United States, 2014-2018. Tuberculosis (Edinb). 2022 Aug 9;136:102232. doi: 10.1016/j.tube.2022.102232. Epub ahead of print. PMID: 35969928.
PMID: 35969928.
Schwartz NG, Hernandez-Romieu AC, Annambhotla P, Filardo TD, Althomsons SP, Free RJ, Li R, Wyatt Wilson W, Deutsch-Feldman M, Drees M, Hanlin E, White K, Lehman KA, Thacker TC, Brubaker SA, Clark B, Basavaraju SV, Benowitz I, Burton Glowicz J, Cowan LS, Starks AM, Bamrah Morris S, LoBue P, Stewart RJ, Wortham JM, Haddad MB; Bone Allograft Tuberculosis Investigators. Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report. Lancet Infect Dis. 2022 Aug 4:S1473-3099(22)00425-X. doi: 10.1016/S1473-3099(22)00425-X. Epub ahead of print. PMID: 35934016.
Shrestha S, Winglee K, Hill A, Shaw T, Smith J, Kammerer JS, Silk BJ, Marks S, Dowdy D. Model-based analysis of tuberculosis genotype clusters in the United States reveals high degree of heterogeneity in transmission, and state-level differences across California, Florida, New York, and Texas. Clin Infect Dis. 2022 Feb 10:ciac121. doi: 10.1093/cid/ciac121. Epub ahead of print. PMID: 35143641.
Smith J, Cohen T, Dowdy D, Shrestha S, Gandhi NR, Hill AN. Quantifying Mycobacterium tuberculosis transmission dynamics across global settings: a systematic analysis. Am J Epidemiol. 2022 Oct 13:kwac181. doi: 10.1093/aje/kwac181. Epub ahead of print. PMID: 36227246.
Smith JP, Modongo C, Moonan PK, Dima M, Matsiri O, Fane O, Click ES, Boyd R, Finlay A, Surie D, Tobias JL, Zetola NM, Oeltmann JE. Tuberculosis attributed to transmission within healthcare facilities, Botswana-The Kopanyo Study. Infect Control Hosp Epidemiol. 2022 Apr 6:1-7. doi: 10.1017/ice.2021.517. Epub ahead of print. PMID: 35382909.
Smith JP, Oeltmann JE, Hill AN, Tobias JL, Boyd R, Click ES, Finlay A, Mondongo C, Zetola NM, Moonan PK. Characterizing tuberculosis transmission dynamics in high-burden urban and rural settings. Sci Rep. 2022 Apr 26;12(1):6780. doi: 10.1038/s41598-022-10488-2. PMID: 35474076; PMCID: PMC9042872.
Stewart RJ, Raz KM, Burns SP, Kammerer JS, Haddad MB, Silk BJ, Wortham JM. Tuberculosis Outbreaks in State Prisons, United States, 2011-2019. Am J Public Health. 2022 Aug;112(8):1170-1179. doi: 10.2105/AJPH.2022.306864. PMID: 35830666.
Tasneen R, Garcia A, Converse PJ, Zimmerman MD, Dartois V, Kurbatova E, Vernon AA, Carr W, Stout JE, Dooley KE, Nuermberger EL. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. Antimicrob Agents Chemother. 2022 Mar 22:e0239821. doi: 10.1128/aac.02398-21. Epub ahead of print. PMID: 35315690.
Tsang CA, Patel NN, Stout JE, Fernando R, Pratt R, Goswami ND. Factors Associated With Receiving Longer Than Recommended Therapy Among Culture-Negative Pulmonary Tuberculosis Patients. Open Forum Infect Dis. 2022 Nov 21;9(12):ofac630. doi: 10.1093/ofid/ofac630. PMID: 36519121; PMCID: PMC9745766.
Walker WL, Schmit KM, Welch EC, Vonnahme LA, Talwar A, Nguyen M, Stojanovic D, Langer AJ, Cocoros NM. Using the Food and Drug Administration ́s Sentinel System for surveillance of TB infection. Int J Tuberc Lung Dis. 2022 Dec 1;26(12):1170-1176. doi: 10.5588/ijtld.22.0259. PMID: 36447322.
Wang Z, Posey DL, Brostrom RJ, Morris SB, Marano N, Phares CR. Post-Arrival Evaluation of Immigrant and Refugee Children in the USA with Latent Tuberculosis Infection Diagnosed Overseas, 2007‒2019. J Pediatr. 2022 Feb 1:S0022-3476(22)00080-4. doi: 10.1016/j.jpeds.2022.01.049. Epub ahead of print. PMID: 35120982.
Winglee K, Hill AN, Belknap R, Stout JE, Ayers T. Variability of interferon-γ release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Feb 17:S1198-743X(22)00094-5. doi: 10.1016/j.cmi.2022.02.020. Epub ahead of print. PMID: 35183749.
Winglee K, Hill AN, Langer AJ, Self JL. Decrease in Tuberculosis Cases during COVID-19 Pandemic as Reflected by Outpatient Pharmacy Data, United States, 2020. Emerg Infect Dis. 2022 Apr;28(4):820-827. doi: 10.3201/eid2804.212014. PMID: 35318920; PMCID: PMC8962886.
							
					
							Last Reviewed:  February 3, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue